MedPath

Eribulin

Generic Name
Eribulin
Brand Names
Halaven, Eribulin Baxter, Mevlyq
Drug Type
Small Molecule
Chemical Formula
C40H59NO11
CAS Number
253128-41-5
Unique Ingredient Identifier
LR24G6354G
Background

Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication

For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions
Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Clinical Trials
Related News

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3
Completed
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2006-06-15
Last Posted Date
2020-06-18
Lead Sponsor
Eisai Inc.
Target Recruit Count
1276
Registration Number
NCT00337103
Locations
🇧🇪

Institut Jules Bordet, Medical Oncology Unit, Brussels, Belgium

🇦🇺

Royal Perth Hospital, Perth, Western Australia, Australia

🇦🇺

Bankstown Hospital, Oncology Trials Unit, Bankstown, New South Wales, Australia

and more 65 locations

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2
Completed
Conditions
Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Primary Peritoneal Cavity Cancer
Interventions
First Posted Date
2006-06-08
Last Posted Date
2017-11-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
74
Registration Number
NCT00334893
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Phase I Clinical Study of E7389

Phase 1
Completed
Conditions
Cancer
Interventions
First Posted Date
2006-05-17
Last Posted Date
2012-03-08
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
15
Registration Number
NCT00326950

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2006-01-19
Last Posted Date
2014-07-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
108
Registration Number
NCT00278993
Locations
🇺🇸

Raleigh Hematology Oncology Associates PL, Raleigh, North Carolina, United States

🇺🇸

Mary Crowley Medical Research Center, Dallas, Texas, United States

🇺🇸

US Oncology, Dallas, Texas, United States

and more 14 locations

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2005-10-30
Last Posted Date
2014-07-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
298
Registration Number
NCT00246090
Locations
🇺🇸

Peachtree Hematology And Oncology Consultants, Atlanta, Georgia, United States

🇺🇸

Central Indiana Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Texas Oncology PA, Houston, Texas, United States

and more 58 locations

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
First Posted Date
2004-11-30
Last Posted Date
2013-04-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
104
Registration Number
NCT00097721

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer
First Posted Date
2003-09-24
Last Posted Date
2012-04-11
Lead Sponsor
Eisai Inc.
Target Recruit Count
21
Registration Number
NCT00069277
Locations
🇺🇸

Cancer Institute Medical Group, Los Angeles, California, United States

🇺🇸

Premiere Oncology, Santa Monica, California, United States

Study of E7389 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2003-09-24
Last Posted Date
2011-12-20
Lead Sponsor
Eisai Inc.
Target Recruit Count
33
Registration Number
NCT00069264

E7389 in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2003-01-27
Last Posted Date
2013-01-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
31
Registration Number
NCT00047034
Locations
🇺🇸

City of Hope, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy